CGCarolina Gallo

Carolina Gallo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carolina Gallo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive quantitative modeling of translation efficiency in a genome‐reduced bacterium

    by Marc Weber, Adrià Sogues, Eva Yus, Raul Burgos, Carolina Gallo, Sira Martínez, Maria Lluch‐Senar, Luis Serrano

    Translation efficiency has been mainly studied by ribosome profiling, which only provides an incomplete picture of translation kinetics. Here, we integrated the absolute quantifications of tRNAs, mRNAs, RNA half‐lives, proteins, and protein half‐lives with ribosome densities and derived the initiation and elongation rates for 475 genes (67% of all genes), 73 with high precision, in the bacterium Mycoplasma pneumoniae ( Mpn ). We found that, although the initiation rate varied over 160‐fold among genes, most of the known factors had little impact on translation efficiency. Local codon elongation rates could not be fully explained by the adaptation to tRNA abundances, which varied over 100‐fold among tRNA isoacceptors. We provide a comprehensive quantitative view of translation efficiency, which suggests the existence of unidentified mechanisms of translational regulation in Mpn .


  • Open Access

    Exploring the adaptability and robustness of the central carbon metabolism of Mycoplasma pneumoniae

    by Niels A. Zondervan, Eva Yus, Daniel C. Sévin, Sira Martinez, Carolina Gallo, Peter J. Schaap, Maria Lluch-Senar, Luis Serrano, Vitor A. P. Martins dos Santos, Maria Suarez-Diez

    In this study we explored the adaptability and robustness of glycolysis and pyruvate metabolism of Mycoplasma pneumoniae ( MPN ). We used a dual approach, we analysed metabolomics data collected for a large number of OE and KO mutants and perturbation samples. Furthermore, we trained a dynamic model of central carbon metabolism and tested the model’s capacity to predict these mutants and perturbation samples as well as identify key controlling factors in central carbon metabolism. Our analysis of metabolite data as well as our model analysis indicate MPN metabolism is inherently robust against perturbations due to its network structure. Two key control hubs of central carbon metabolism were identified.

  • Open Access

    Engineering a genome‐reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo

    by Victoria Garrido, Carlos Piñero‐Lambea, Irene Rodriguez‐Arce, Bernhard Paetzold, Tony Ferrar, Marc Weber, Eva Garcia‐Ramallo, Carolina Gallo, María Collantes, Iván Peñuelas, et al.

    Bacteria present a promising delivery system for treating human diseases. Here, we engineered the genome‐reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm‐associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to most other bacterial genera, and it lacks a cell wall, which allows it to express proteins that target peptidoglycans of pathogenic bacteria. We first determined that removal of the pathogenic factors fully attenuated the chassis strain in vivo . We then designed synthetic promoters and identified an endogenous peptide signal sequence that, when fused to heterologous proteins, promotes efficient secretion. Based on this, we equipped the chassis strain with a genetic platform designed to secrete antibiofilm and bactericidal enzymes, resulting in a strain capable of dissolving Staphylococcus aureus biofilms preformed on catheters in vitro , ex vivo , and in vivo . To our knowledge, this is the first engineered genome‐reduced bacterium that can fight against clinically relevant biofilm‐associated bacterial infections.


  • Open Access

    Widespread ribosome stalling in a genome-reduced bacterium and the need for translational quality control

    by Raul Burgos, Marc Weber, Carolina Gallo, Maria Lluch-Senar, Luis Serrano